title: [Study KBP-2010-CPHG: inclusion of new cases of primary lung cancer diagnosed in general hospital pneumology departments between 1st January and 31 December 2010].
abstract: BACKGROUND
  The College of General Hospital Respiratory Physicians (CPHG) is following up the KBP-2000-CPHG study, performed ten years ago, with a new observational epidemiological study of primary lung cancer.
  
  
  METHODS
  The study includes all new cases of primary lung cancer diagnosed on histology or cytology between 1 January and 31 December 2010 and managed by one of the general hospital pneumology departments participating in the study. The primary objective is to estimate five-year mortality and to analyze risk factors. Secondary objectives are to describe the characteristics of this patient population and their management, and to estimate one, four and five-year survival rates. These data will be compared to those of the KBP-2000-CPHG study. The four-year prognosis score developed in 2000 will also be assessed in the new study. Data are collected by standardized questionnaire with exhaustiveness control.
  
  
  RESULTS
  One hundred and eight investigating centers have agreed to participate; 4000 to 5000 new cases of primary lung cancer should be collected and analyzed.
  
  
  CONCLUSIONS
  The study will describe the characteristics of patients presenting with primary lung cancer in the participating pneumology departments during the year 2010, and their diagnostic and therapeutic management, and assess changes over the last ten years.
authors.affiliation: Service de pneumologie, centre hospitalier de Meaux, 6-8 rue Saint-Fiacre, BP 218, 77104 Meaux cedex, France. m-grivaux@ch-meaux.fr
authors.forename: M
authors.initials: M
authors.lastname: Grivaux
authors.forename: C
authors.initials: C
authors.lastname: Locher
authors.forename: P
authors.initials: P
authors.lastname: Bombaron
authors.forename: T
authors.initials: T
authors.lastname: Collon
authors.forename: D
authors.initials: D
authors.lastname: Coëtmeur
authors.forename: C
authors.initials: C
authors.lastname: Dayen
authors.forename: D
authors.initials: D
authors.lastname: Debieuvre
authors.forename: F
authors.initials: F
authors.lastname: Goupil
authors.forename: J
authors.initials: J
authors.lastname: Le Treut
authors.forename: F
authors.initials: F
authors.lastname: Martin
authors.forename: O
authors.initials: O
authors.lastname: Molinier
authors.forename: B
authors.initials: B
authors.lastname: Asselain
authors.forename: M
authors.initials: M
authors.lastname: Zureik
authors.forename: F
authors.initials: F
authors.lastname: Blanchon
mesh_terms: D000328:Adult; D015331:Cohort Studies; D003131:Combined Modality Therapy; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000235:genetics; D005602:France; D006769:Hospitals, General; D006801:Humans; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D009687:Nuclear Proteins / Q000235:genetics; D011159:Population Surveillance; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors / Q000235:genetics
chemical_list: D009687:Nuclear Proteins; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors; C512478:EGFR protein, human; D066246:ErbB Receptors